Findlay M P, Cunningham D, Morgan G, Clinton S, Hardcastle A, Aherne G W
Institute of Cancer Research and the Royal Marsden Hospital, Sutton, Surrey.
Br J Cancer. 1997;75(6):903-9. doi: 10.1038/bjc.1997.159.
The increasing interest in 5-fluorouracil (5-FU) modulation and the development of new antifolates has focused attention in recent studies on the expression of the target enzyme thymidylate synthase (TS) as a determinant of drug sensitivity and resistance. Resistance to TS-directed drugs has been shown to occur in vitro and in vivo with increased expression of the enzyme (determined by enzymatic assays as well as protein and gene expression assays). Several studies have evaluated the role of TS as a prognostic indicator of clinical response to chemotherapy containing TS-directed drugs. We have used a polyclonal antibody to recombinant human TS to establish a silver-enhanced immunogold staining method to localize TS in human tumours. Human tumour cell lines with acquired resistance to TS inhibitors owing to increased levels of TS were used to confirm the specificity of immunostaining. Stained sections were evaluated by image analysis. Immunostaining in tumour sections was greatly reduced (>80%) by preabsorption of the antiserum with recombinant TS. The method was used to determine the extent of TS immunostaining in 134 primary human colorectal tumours. The results were then compared with the clinical outcome and response to chemotherapy for the treatment of subsequent metastatic disease. A wide range (approximately 100-fold) of TS immunostaining was observed in these primary tumour sections. Normal mucosal tissue levels were 5-10 times lower than those observed in the adjacent tumour tissue. The values for TS immunostaining did not correlate with clinical endpoints, such as time from diagnosis to relapse, response to chemotherapy for disseminated disease, nor with Dukes' staging. This lack of correlation may be because this group of patients was selected on the basis of their need for palliative chemotherapy and did not include patients who were cured of their disease. Also, primary tumour TS expression may not give a good indication of the TS expression in metastatic lesions. The prognostic significance of TS protein expression in primary and metastatic lesions requires further evaluation.
对5-氟尿嘧啶(5-FU)调节的兴趣日益增加以及新型抗叶酸剂的开发,使得近期研究将注意力集中在靶酶胸苷酸合成酶(TS)的表达上,将其作为药物敏感性和耐药性的决定因素。已表明,随着该酶表达增加(通过酶活性测定以及蛋白质和基因表达测定确定),在体外和体内会出现对TS导向药物的耐药性。多项研究评估了TS作为含TS导向药物化疗临床反应预后指标的作用。我们使用针对重组人TS的多克隆抗体建立了一种银增强免疫金染色方法,以在人肿瘤中定位TS。使用因TS水平升高而对TS抑制剂获得性耐药的人肿瘤细胞系来确认免疫染色的特异性。通过图像分析评估染色切片。用重组TS预吸收抗血清后,肿瘤切片中的免疫染色大大降低(>80%)。该方法用于确定134例原发性人大肠癌肿瘤中TS免疫染色的程度。然后将结果与后续转移性疾病治疗的临床结果和化疗反应进行比较。在这些原发性肿瘤切片中观察到TS免疫染色范围广泛(约100倍)。正常黏膜组织水平比相邻肿瘤组织中观察到的水平低5-10倍。TS免疫染色值与临床终点无关,如从诊断到复发的时间、对播散性疾病化疗的反应,也与Dukes分期无关。这种缺乏相关性可能是因为该组患者是根据其姑息化疗需求选择的,不包括疾病已治愈的患者。此外,原发性肿瘤TS表达可能无法很好地指示转移性病变中的TS表达。TS蛋白表达在原发性和转移性病变中的预后意义需要进一步评估。